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Treatment consists of oral valaciclovir (Zelitrex) for 10 days
as well as topical mupirocin (Bactroban) ointment for the
scabs. It is vital not to let the lesions dry out, as this can
lead to cicatrisation and lid disorders such as entropion
with resultant corneal scarring. Pain can be debilitating and
is alleviated by topical EMLA cream, capsacain and oral
carbamazepine ITegretol).
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KAPOSI'S SARCOMA
Herpetic ulcers of the cornea in HIV-infected patients tend
to be peripheral rather than central, and to be large
dendritic ulcers. Treatment is with acyclovir (Zovirax)
ointment 5 times a day, and patients should be monitored
for uveitis.
Lesions are multiple and large, and accumulate on the lids.
Cryotherapy is used to treat clinically significant lesions.
Uveitis and an accompanying rise in intraocular pressure
are seen in up to 40% of patients. Referral to an
ophthalmologist is prudent to avoid complications.
SQUAMOUS CARCINOMA OF THE CONJUNCTNA
MOllUSCUM CONTAGIOSUM
These blue-black vascular tumours can affect the eyelids or
conjunctiva. Treatment is necessary for large, sight-
threatening lesions and is normally accomplished by
cryotherapy.
Squamous carcinoma of the conjunctiva has rapidly
become a new marker for HIV in young patients (Figs 2 and
3). Typically they are younger than 40 years, whereas the
normal age for appearance of this tumour is 65 years.
The spectrum of disease extends from pterygium through
dysplasia to carcinoma in situ. Typical lesions are raised,
with large feeder blood vessels and uneven, rough surfaces.
Pigmentation is common.
Treatment involves careful excision using Moh's
micrographic technique. It is important not to breach the
corneal Bruch's membrane as this can lead to local
recurrence. Adjuvant therapies include mitomycin
antimetabolite, radiotherapy and enucleation of eyes if
HERPES ZOSTER
Fig. 1. Herpes zoster.
SURFACE PATHOLOGY
Almost 7(JJ/o of untreated AIDS patients will develop ocular
manifestations, more than half of which are associated
with ocular infiammation or uveitis. It is the aim of this
article to highlight the common and important conditions
that the practitioner might come across.
OCULAR MANIFESTATIONS OF HIV/AIDS
The practice of the ophthalmologist who looks after people
with HN has changed.
The widespread use of highly active antiretroviral therapy
(HAARn has reduced the incidence of cytomegalovirus
(CMY) retinitis as well as other opportunistic infections. It
must be remembered that iatrogenic complications also
arise, e.g. colour vision impairment by zidovudine and
uveitis associated with cidofovir and rifabutin.
For convenience, we can group the conditions into surface
disorders, neuro-ophthalmological complications, vascular
manifestations and uveitis.
Herpes zoster has become a prominent marker for HIV
infection (Fig. 1). Traditionally this condition affects
patients older than 60 years. With HIV, we are seeing
patients younger than 45 years. The disease tends to be
very aggressive, with prominent crusting and neuralgia. The
CD4+ count is usually 75 - 150 cells/~1.
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UVEITIS
Ag. 4. Early CMValong vascular arcade.
Ag. 5. Established CMV with retinal oedema.
Necrotising retinitis is caused by CMV, varicella and herpes
zoster. CMV is the most common, and usually occurs with
a CD4+ count of less than 50 cells/~1.
Other causes of uveitis include:
• Toxoplasmosis [llJlltl of HIV patients). Can be single or
multiple white foci with overlying vitritis.
• Lymphoma with infiltrates.
• Endogenous endophthalmitis in intravenous drug users,
leading to retinal abscess.
• Bilateral multifocal choroiditis caused by Pneumocystis
carinii or cryptococcus. This tends to occur as an
epiphenomenon of systemic/central nervous system
disease.
cryptococcosis. Optic neuritis is treated by antivirals and
corticosteroids according to severity. Causative organisms
are often not isolated, leading to the hypothesis that HIV
itself causes optic neuritis.
CMV retinitis can have various appearances [Figs 4 and 5).
The traditional description of 'cottage cheese and ketchup'
with haemorrhages can follow an indolent or granular
appearance. The leading edge of the lesion can assume a
'brushfire' appearance around the necrotic, pale retina [Fig.
6). Sheathing of the vessels can produce a spectacular
VASCULOPATHY
Ag. 2. Squamaus carcinama af the canjunctiva.
Ag. 3. Neglected squamous carcinoma.
NEURO-OPHTHALMOLOGICAL PATHOLOGY
there is local invasion. Spread to adjacent tissues requires
exenteration of the orbital contents.
Neuro-ophthalmological disease includes optic neuritis,
papilloedema, cranial nerve palsies and visual field deficits
due to intracranial disease such as toxoplasmosis and
These lesions usually resolve spontaneously and can be
confused with early CMV retinitis.
Vasculopathy takes the form of a microangiopathy that
manifests as cottonwool spots in the retina. It occurs in
50 - 7lJlltl of AIDS patients and can look like early diabetic
retinopathy. Small dot haemorrhages are common.
Rg. 6. '8rushfire' edge ofCMVretinitis.
Rg. 7. 'Frosted-branch' angiitis.
Rg. 8. Healed CMV with retinal atrophy and pigmentation.
'frosted-branch angiitis' (Fig. 7). In response to treatment,
the active white border turns grey (Fig. 8). Haemorrhages
can persist for months. Fibrosis and pigmentation are
common in healed lesions.
On HAART, patients with previously quiescent disease can
experience the phenomenon of immune-ret:overy uveitis.
This usually occurs after elevation of the CD4+ count above
60 cells/~1. No concurrent relapse of CMV retinitis is noted.
Vitreous haze, retinal and optic nerve oedema and
formation of epiretinal membranes are noted. Treatment is
with periocular and systemic steroids.
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Various agents have been used to treat CMV retinitis.
Intravenous agents have the advantage of treating both
eyes and systemic disease. These include:
• Foscarnet - daily dose with side-effet:ts of nausea
(40'1'0) and renal impairment
• Cidofovir - induction and then weekly. Complications
are uveitis and hypotony.
• Ganciclovir - induction and then daily 5 times a weeil
This can cause bone-marrow suppression.
Relapse of disease within months is common on IV
treatment.
Ganciclovir implants have proven effective but carry the
risk of haemorrhage and retinal detachment (12%) and
need to be replaced every 6 - 8 months.
Intravitreal ganciclovir injmions (Fig. 9) have proved
very effective in the South African setting where HAART is
still not freely available. These are cheap (20 treatments per
vial of ganciclovir) and after the initial twice-weekly
induction are given weekly and then every 2 weeks. The
addition of oral ganciclovir improves the outcome.
Rg. 9. Introvitreal ganciclovir injection.
Recent studies have shown that it may not be necessary to
continue CMV therapy in patients on HAART. Normally,
without immune restitution or maintenance therapy CMV
retinitis relapses within 3 weeks. In patients on HAART,
relapses occur up to 6 months. After this period, if the
C04+ count is above 50 cellsM the patient can be
monitored without CMV therapy.
After 18 months on HAART, if there has been no ret:urrence
of CMV it is highly unlikely to recur even if the C04+ count
does not rise above 100 cells/~1. Any drop below 50 cells/~I,
however, can lead to recurrence.
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